Top Page
Kangji Medical Holdings Limited
(Frankfurt:9997)
Kangji Medical Holdings Limited (9997) vs. iShares MSCI Hong Kong ETF (EWH)
Kangji Medical Holdings Limited Business Overview & Revenue Model
Kangji Medical Holdings Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.01B | 926.02M | 786.37M | 690.26M | 511.49M | Gross Profit |
| 797.65M | 741.20M | 635.25M | 562.93M | 431.47M | EBIT |
| 592.69M | 442.47M | 446.02M | 417.74M | 311.67M | EBITDA |
| 562.61M | 464.58M | 586.65M | 427.25M | 319.14M | Net Income Common Stockholders |
| 581.44M | 504.02M | 478.74M | 456.79M | 250.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.24B | 2.69B | 2.83B | 3.01B | 2.78B | Total Assets |
| 2.92B | 4.26B | 3.98B | 3.39B | 3.02B | Total Debt |
| 3.52M | 43.99M | 49.02M | 4.05M | 5.05M | Net Debt |
| -1.12B | -2.63B | -2.77B | -2.95B | -2.23B | Total Liabilities |
| 289.39M | 319.97M | 266.10M | 129.94M | 83.65M | Stockholders Equity |
| 2.63B | 3.65B | 3.37B | 3.26B | 2.94B |
| Cash Flow | Free Cash Flow | |||
| 504.52M | 331.70M | 243.62M | 404.88M | 203.21M | Operating Cash Flow |
| 560.10M | 419.62M | 319.31M | 435.75M | 221.04M | Investing Cash Flow |
| 1.04B | -391.70M | -369.98M | -160.09M | -610.98M | Financing Cash Flow |
| -1.70B | -243.53M | -472.79M | -97.61M | 2.15B |
Kangji Medical Holdings Limited Technical Analysis
Kangji Medical Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | €9.37B | 14.42 | 18.36% | 3.78% | 7.13% | 13.39% | |
81 Outperform | €1.64B | 10.67 | 3.72% | 8.36% | 11.84% | -2.22% | |
77 Outperform | $27.90B | 12.27 | 8.95% | 4.36% | -3.09% | 0.67% | |
66 Neutral | HK$4.51B | 20.16 | 11.24% | 1.18% | 11.23% | 20.39% | |
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% |
Kangji Medical Holdings Limited Corporate Events
Kangji Medical Holdings Limited has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement highlights the company’s governance structure, which includes a mix of executive, non-executive, and independent non-executive directors, potentially impacting its strategic direction and stakeholder confidence.
Kangji Medical Holdings Limited announced the results of its Annual General Meeting held on May 23, 2025. All proposed resolutions, including the approval of financial statements, declaration of dividends, re-election of directors, and granting of mandates for share issuance and buyback, were passed with significant majorities. These resolutions reflect the company’s stable governance and strategic direction, potentially impacting its market operations and shareholder value positively.
Kangji Medical Holdings Limited has announced the election of currency options for its final dividend payment for the year ended December 31, 2024. Shareholders can choose to receive the dividend in either Renminbi or Hong Kong Dollars, providing flexibility in currency preference. This decision reflects the company’s commitment to accommodating shareholder needs and could potentially enhance shareholder satisfaction by offering a choice in dividend currency. The final dividend is set at RMB 24 cents per share, with an equivalent of HKD 26.13 cents per share, based on the exchange rate published by the People’s Bank of China.
Kangji Medical Holdings Limited has announced an update regarding the payment of its final dividend for the year ended December 31, 2024. Shareholders will receive a dividend of RMB 0.24 per share, with an option to receive the payment in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.08875. The payment date is set for July 16, 2025, with the closing date for currency option election on June 23, 2025. This announcement reflects the company’s commitment to providing returns to its shareholders and may influence investor sentiment positively.
Kangji Medical Holdings Limited announced changes to its Nomination Committee, effective May 23, 2025. Ms. Shentu Yinguang has been appointed as a member, while Mr. Zhong Ming has stepped down as chairman and member, and Mr. Jiang Feng has been appointed as the new chairman. These changes align with amendments to the Hong Kong Stock Exchange’s Listing Rules and Corporate Governance Code, aiming to improve board effectiveness and diversity, thereby enhancing the company’s corporate governance practices.
Kangji Medical Holdings Limited announced the termination of a discloseable transaction involving the disposal of a subsidiary due to the purchaser’s inability to fulfill payment obligations. The termination agreement allows Kangji to retain RMB46 million and includes provisions for the return of company records and land resumption. Additionally, Kangji entered a land resumption agreement with a PRC government authority, resulting in a compensation of approximately RMB29.3 million. The company expects to realize a gain of RMB39.3 million from these agreements, impacting its financial position positively.
Kangji Medical Holdings Limited has announced its upcoming annual general meeting scheduled for May 23, 2025, in Hong Kong. Key agenda items include the approval of audited financial statements for 2024, a final dividend declaration of RMB24 cents per share, re-election of independent non-executive directors, and re-appointment of Ernst & Young as auditors. The meeting will also address resolutions concerning the issuance and management of company shares, indicating a strategic focus on financial stability and governance.
Kangji Medical Holdings Limited announced that its associate, Hangzhou Weijing Medical Robot Co., Ltd., has received regulatory approval from China’s National Medical Products Administration for its four-arm laparoscopic surgical robot. This approval marks a significant milestone in Weijing Medical’s commercialization efforts and strengthens Kangji Medical’s strategic position in the minimally invasive surgery market. The company plans to leverage its sales, distribution, and manufacturing capabilities to support the development and commercialization of Weijing Medical’s surgical robotic systems.